
|Articles|April 22, 2015
- Melanoma (Issue 4)
- Volume 4
- Issue 1
Toxicity of Immunotherapies in Melanoma
Author(s)Jeffrey S. Weber, MD, PhD
Jeffrey S. Weber, MD, PhD, a senior member at Moffitt Cancer Center, discusses toxicities associated with immunotherapies for the treatment of patients with melanoma.
Advertisement
Jeffrey S. Weber, MD, PhD, a senior member at Moffitt Cancer Center, discusses toxicities associated with immunotherapies for the treatment of patients with melanoma.
<<<
Articles in this issue
almost 11 years ago
Unprecedented Response Rates Seen With Ipilimumab Plus Nivolumab in Melanomaalmost 11 years ago
Comparing Two Doses of Ipilimumabalmost 11 years ago
New Standards Needed to Lessen Surgery Delays in Melanomaalmost 11 years ago
Neoantigens for Personalized Immunotherapy May Boost Melanoma Treatmentalmost 11 years ago
Gene Removal May Pose Future Treatment in Advanced Melanomaalmost 11 years ago
The Development of T-VEC for Melanomaalmost 11 years ago
The Role of Macrophages in BRAF Inhibitor ResistanceAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















